Status: Recruiting
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Participants needed: 8,680
Trial details
Biological sex: AllType: ObservationalSponsor: Centers for Medicare and Medicaid Services/ Coverage and Analysis GroupUpdated: Sep 28, 2023Locations: 1
Eligibility criteria
Medicare patients with a clinical diagnosis of mild cognitive impairment due to...
none